- £43.40m
- £46.60m
- $29.49m
- 48
- 21
- 82
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 358.2 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.78 | ||
| Price to Tang. Book | 3.58 | ||
| Price to Free Cashflow | 303.36 | ||
| Price to Sales | 1.82 | ||
| EV to EBITDA | 98.88 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.02% | ||
| Return on Equity | -5.58% | ||
| Operating Margin | -1.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.63 | 16.45 | 19.75 | 24.48 | 29.49 | 38.22 | 43.78 | 13.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.
Directors
- Jonathan Glenn NEC (45)
- Daniel Lee CEO (64)
- David Cocke CFO (55)
- Kirsten Lund FID
- Patti Gary VPR
- Lance Johnson VPR
- Gerald Sharpe VPR
- Tina Trimble VPR
- Christine Rowley OTH
- Shervanthi Homer-vanniasinkam NED (63)
- Brian Phillips NID
- Trevor Phillips NID (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 17th, 2006
- Public Since
- December 21st, 2006
- No. of Employees
- 76
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 70,574,468
- Address
- Unit 3, LEEDS, LS25 2GY
- Web
- https://www.tissueregenix.com/
- Phone
- +44 1904567609
- Auditors
- RSM UK Audit LLP
Latest News for TRX
Upcoming Events for TRX
Tissue Regenix Group PLC Annual Shareholders Meeting
Tissue Regenix Group PLC Annual Shareholders Meeting
Half Year 2024 Tissue Regenix Group PLC Earnings Release
Similar to TRX
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Advanced Oncotherapy
London Stock Exchange
Angle
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 19:21 UTC, shares in Tissue Regenix are trading at 61.50p. This share price information is delayed by 15 minutes.
Shares in Tissue Regenix last closed at 61.50p and the price had moved by +1.65% over the past 365 days. In terms of relative price strength the Tissue Regenix share price has outperformed the FTSE All Share Index by +1.7% over the past year.
The overall consensus recommendation for Tissue Regenix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Tissue Regenix does not currently pay a dividend.
Tissue Regenix does not currently pay a dividend.
Tissue Regenix does not currently pay a dividend.
To buy shares in Tissue Regenix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 61.50p, shares in Tissue Regenix had a market capitalisation of £43.40m.
Here are the trading details for Tissue Regenix:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: TRX
Based on an overall assessment of its quality, value and momentum Tissue Regenix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Tissue Regenix is 120.00p. That is 95.12% above the last closing price of 61.50p.
Analysts covering Tissue Regenix currently have a consensus Earnings Per Share (EPS) forecast of -$0.00 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tissue Regenix. Over the past six months, its share price has outperformed the FTSE All Share Index by +4.49%.
As of the last closing price of 61.50p, shares in Tissue Regenix were trading +7.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tissue Regenix PE ratio based on its reported earnings over the past 12 months is 358.2. The shares last closed at 61.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Tissue Regenix's management team is headed by:
- Jonathan Glenn - NEC
- Daniel Lee - CEO
- David Cocke - CFO
- Kirsten Lund - FID
- Patti Gary - VPR
- Lance Johnson - VPR
- Gerald Sharpe - VPR
- Tina Trimble - VPR
- Christine Rowley - OTH
- Shervanthi Homer-vanniasinkam - NED
- Brian Phillips - NID
- Trevor Phillips - NID